TR200402435T4 - 3-piridil-1-hidroksietiliden-1,1-bisfosfonik asit sodyumun hemipentahidrat veya monohidrat olarak seçici şekilde kristalleştirilmesi. - Google Patents

3-piridil-1-hidroksietiliden-1,1-bisfosfonik asit sodyumun hemipentahidrat veya monohidrat olarak seçici şekilde kristalleştirilmesi.

Info

Publication number
TR200402435T4
TR200402435T4 TR2004/02435T TR200402435T TR200402435T4 TR 200402435 T4 TR200402435 T4 TR 200402435T4 TR 2004/02435 T TR2004/02435 T TR 2004/02435T TR 200402435 T TR200402435 T TR 200402435T TR 200402435 T4 TR200402435 T4 TR 200402435T4
Authority
TR
Turkey
Prior art keywords
monohydrate
hemipentahydrate
hydroxyethylidene
pyridyl
acid sodium
Prior art date
Application number
TR2004/02435T
Other languages
English (en)
Inventor
Dana Cazer Fredrick
Eugene Perry Gregory
Micheal Billings Dennis
Lee Redman Furey Nancy
Original Assignee
The Procter & Gamble Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22656866&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR200402435(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The Procter & Gamble Company filed Critical The Procter & Gamble Company
Publication of TR200402435T4 publication Critical patent/TR200402435T4/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/58—Pyridine rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Mevcut bulus,3-piridil-1-hidroksietiliden-1,1-bisfosfonik asit sodyum hemipentahidrat ve monohidrati, çekirdeklesme sicakliginin ve kristallesme hizinin kontrol edilmesini içeren hemipentahidrat veya monohidrat hazirlama yöntemlerini hidrat formlarindan birini veya her ikisini de içeren farmasötik bilesimleri tarif etmektedir.
TR2004/02435T 2000-02-01 2001-02-01 3-piridil-1-hidroksietiliden-1,1-bisfosfonik asit sodyumun hemipentahidrat veya monohidrat olarak seçici şekilde kristalleştirilmesi. TR200402435T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17950500P 2000-02-01 2000-02-01

Publications (1)

Publication Number Publication Date
TR200402435T4 true TR200402435T4 (tr) 2004-12-21

Family

ID=22656866

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2004/02435T TR200402435T4 (tr) 2000-02-01 2001-02-01 3-piridil-1-hidroksietiliden-1,1-bisfosfonik asit sodyumun hemipentahidrat veya monohidrat olarak seçici şekilde kristalleştirilmesi.

Country Status (33)

Country Link
US (1) US6410520B2 (tr)
EP (1) EP1252170B2 (tr)
JP (5) JP2003521532A (tr)
KR (1) KR100549038B1 (tr)
CN (1) CN1183148C (tr)
AR (1) AR030187A1 (tr)
AT (1) ATE273984T1 (tr)
AU (1) AU784307B2 (tr)
BR (1) BRPI0107921B8 (tr)
CA (1) CA2399976C (tr)
CO (1) CO5271720A1 (tr)
CZ (1) CZ303400B6 (tr)
DE (1) DE60104978T3 (tr)
DK (1) DK1252170T4 (tr)
ES (1) ES2225481T5 (tr)
HK (1) HK1051046B (tr)
HU (1) HU230494B1 (tr)
IL (2) IL150511A0 (tr)
MA (1) MA25654A1 (tr)
MX (1) MXPA02007417A (tr)
MY (1) MY119968A (tr)
NO (1) NO329923B1 (tr)
NZ (1) NZ519966A (tr)
PE (1) PE20011061A1 (tr)
PL (1) PL207589B1 (tr)
PT (1) PT1252170E (tr)
RU (1) RU2236415C2 (tr)
SA (1) SA01220066B1 (tr)
SK (1) SK287884B6 (tr)
TR (1) TR200402435T4 (tr)
TW (1) TWI310769B (tr)
WO (1) WO2001056983A2 (tr)
ZA (1) ZA200205090B (tr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20011061A1 (es) * 2000-02-01 2001-11-20 Procter & Gamble Cristalizacion selectiva del acido 3-piridil-1-hidroxi-etiliden-1,1-bisfosfonico sodio como el hemipentahidrato o el monohidrato
US20030195170A1 (en) * 2002-04-11 2003-10-16 Judith Aronhime Novel polymorphs and pseudopolymorphs of risedronate sodium
EP1923052A1 (en) 2002-04-11 2008-05-21 Teva Pharmaceutical Industries Ltd Novel polymorphs and pseudopolymorphs of risedronate sodium
CZ20023574A3 (en) * 2002-10-25 2004-04-14 Léčiva, A.S. New crystalline form of the sodium salt of 3-pyridyl-1-hydroxyehtylidene-1,1-bisphosphonic acid
CA2513543A1 (en) * 2003-01-17 2004-08-05 Teva Pharmaceutical Industries Ltd. Risedronate sodium having a very low content of iron
HUP0300227A2 (hu) * 2003-01-28 2004-09-28 Richter Gedeon Vegyészeti Gyár Rt. Eljárás nagy tisztaságú 2-szubsztituált -1-(hidroxi-etilidén)-1,1-biszfoszfonsavak és sóik előállítására
ATE493423T1 (de) * 2003-07-30 2011-01-15 Warner Chilcott Co Llc Verfahren zur steuerung der kristallstruktur von risedronat
CZ298639B6 (cs) * 2004-02-05 2007-12-05 Zentiva, A. S. Krystalická forma risedronátu monosodného
WO2005082915A1 (en) * 2004-02-26 2005-09-09 Zentiva, A.S. Amorphous forms of risedronate monosodium
WO2005107714A2 (en) * 2004-05-05 2005-11-17 Alkermes Controlled Therapeutics, Inc. Method of forming microparticles that include a bisphosphonate and a polymer
CA2566798A1 (en) 2004-05-24 2005-12-08 The Procter & Gamble Company Enteric solid oral dosage form of bisphosphonate containing a chelating agent
WO2006039721A2 (en) * 2004-10-08 2006-04-13 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases
US8012949B2 (en) * 2004-10-08 2011-09-06 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods with enhanced potency for multiple targets including FPPS, GGPPS, and DPPS
US7687482B2 (en) * 2006-03-17 2010-03-30 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods
WO2006051553A1 (en) * 2004-11-09 2006-05-18 Jubilant Organosys Limited Process for preparing a pure polymorphic form of 3-pyridyl-1-hydroxyethylidine-1,1-bisphosphonic acid sodium salt
PL199215B1 (pl) * 2004-12-28 2008-08-29 Politechnika Gdanska Sposób wytwarzania kwasu [1-hydroksy-2-(3-pirydylo)etylidenobisfosfonowego] oraz jego soli monosodowej dwu i pół wodnej
EP1883644A2 (en) * 2005-05-06 2008-02-06 Medichem, S.A. Process of making geminal bisphosphonic acids and pharmaceutically acceptable salts and/or hydrates thereof
US7872144B2 (en) * 2005-06-13 2011-01-18 Jubilant Organosys Limited Process for producing biphosphonic acids and forms thereof
AR054673A1 (es) * 2005-07-28 2007-07-11 Gador Sa Una forma cristalina del acido zoledronico, un proceso para su obtencion y la composicion farmaceutica que la comprende
GB0519891D0 (en) * 2005-09-30 2005-11-09 Pliva Hrvatska D O O Pharmaceutically acceptable salts and hydrates
WO2007042048A2 (en) * 2005-10-11 2007-04-19 Sandoz A/S Method for preparing crystalline sodium risedronate
EP1775302A1 (en) * 2005-10-11 2007-04-18 Sandoz A/S Method for preparing crystalline sodium risedronate
WO2007083243A2 (en) * 2006-01-20 2007-07-26 Aurobindo Pharma Limited An improved process for the preparation of risedronate sodium hemi-pentahydrate
JP5354858B2 (ja) * 2006-05-09 2013-11-27 株式会社Ａｄｅｋａ スルホンアミド化合物の金属塩を含有するポリエステル樹脂組成物
BRPI0710421A2 (pt) 2006-05-11 2011-08-09 Ind Swift Ltd processo para a preparação de ácido risedrÈnico puro ou sais
AU2007270897A1 (en) * 2006-07-03 2008-01-10 Generics [Uk] Limited Novel process for the preparation of bisphosphonic acids
WO2008065542A2 (en) * 2006-09-22 2008-06-05 Orchid Chemicals & Pharmaceuticals Ltd. An improved process for the preparation of risedronate sodium
WO2008044245A2 (en) * 2006-10-10 2008-04-17 Matrix Laboratories Ltd A process for the preparation of risedronate sodium hemipentahydrate
KR100828705B1 (ko) 2006-12-04 2008-05-09 씨제이제일제당 (주) 리세드론산 나트륨 수화물의 제조방법
KR100775440B1 (ko) * 2006-12-20 2007-11-12 동우신테크 주식회사 리세드로네이트 나트륨 헤미펜타히드레이트의 제조방법
KR100798855B1 (ko) * 2007-02-14 2008-01-28 주식회사 엔지켐 리세드론산 나트륨 헤미펜타하이드레이트의 제조방법
KR100812528B1 (ko) * 2007-04-12 2008-03-12 보령제약 주식회사 리세드로네이트 나트륨염의 헤미펜타히드레이트의 선택적결정화방법
US20100317859A1 (en) * 2007-05-16 2010-12-16 Actavis Group Ptc Ehf Process for the Preparation of Risedronate Sodium
WO2009050731A2 (en) * 2007-06-20 2009-04-23 Alkem Laboratories Ltd Novel process for preparing risedronic acid
DE102007030370A1 (de) 2007-06-29 2009-01-02 Ratiopharm Gmbh Essigsäure-Solvate von Risedronat, Polymorph hiervon, deren Herstellung und Verwendung sowie pharmazeutische Zusammensetzung, enthaltend diese
KR100925835B1 (ko) * 2007-12-07 2009-11-06 동우신테크 주식회사 리세드로네이트 나트륨 무수물 및 수화물의 제조방법
KR101010062B1 (ko) 2008-04-11 2011-01-21 주식회사 대희화학 증발 결정화를 이용한 결정상 리세드로네이트 모노소듐모노하이드레이트의 제조방법
WO2011054182A1 (zh) * 2009-11-03 2011-05-12 Liu Li 丹参酮ⅱa磺酸钠水合物及其制备方法和用途
AU2016291163B2 (en) * 2015-07-08 2020-01-23 Daiichi Sankyo Company, Limited Pyridine compounds
EP4163313A1 (en) 2017-06-06 2023-04-12 Mitsubishi Chemical Corporation Polyorganosiloxane-containing graft copolymer, thermoplastic resin composition, and molded article

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2534391C2 (de) 1975-08-01 1983-01-13 Henkel KGaA, 4000 Düsseldorf 1-Hydroxy-3-aminoalkan-1,1-diphosphonsäuren
US4447256A (en) 1977-07-20 1984-05-08 Nissan Chemical Industries, Ltd. N-(Unsubstituted or substituted pyridyl)aminomethylene-diphosphonic acids, herbicidal compositions containing same, their use for herbicides, and process for preparing same
DE2745083C2 (de) 1977-10-07 1985-05-02 Henkel KGaA, 4000 Düsseldorf Hydroxydiphosphonsäuren und Verfahren zu deren Herstellung
US4330537A (en) 1977-12-07 1982-05-18 The Procter & Gamble Company Compositions for inhibiting mobilization of calcium phosphate in animal tissue
JPS5598193A (en) 1979-01-22 1980-07-25 Nissan Chem Ind Ltd Methylenediphosphonic acid derivative and herbicide comprising it as active constituent
DE2943498C2 (de) 1979-10-27 1983-01-27 Henkel KGaA, 4000 Düsseldorf Verfahren zur Herstellung von 3-Amino-1-hydroxypropan-1,1-diphosphonsäure
DE3016289A1 (de) 1980-04-28 1981-10-29 Henkel KGaA, 4000 Düsseldorf Verfahren zur herstellung von omega -amino-1-hydroxyalkyliden-1,1-bis-phosphonsaeuren
US4304734A (en) 1980-10-16 1981-12-08 Vysoka Skola Chemicko-Technologicka 6-Amino-1-hydroxyhexylidene diphosphonic acid, salts and a process for production thereof
DE3151038A1 (de) 1981-12-23 1983-07-28 Henkel KGaA, 4000 Düsseldorf Verfahren zur herstellung von 3-amino-1-hydroxypropan-1,1-diphosphonsaeure
IT1201087B (it) 1982-04-15 1989-01-27 Gentili Ist Spa Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche
DE3428524A1 (de) * 1984-08-02 1986-02-13 Boehringer Mannheim Gmbh, 6800 Mannheim Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
IT1196315B (it) 1984-10-29 1988-11-16 Gentili Ist Spa Procedimento per la preparazione di acidi difosfonici
PH27078A (en) * 1984-12-21 1993-02-01 Procter & Gamble Pharmaceutical compositions containing geminal diphosphonates
IL77243A (en) 1984-12-21 1996-11-14 Procter & Gamble Pharmaceutical compositions containing geminal diphosphonic acid compounds and certain such novel compounds
IT1187750B (it) 1985-10-15 1987-12-23 Eurand Spa Procedimento per la preparazione di compresse,anche a rilascio prolungato,di iscsorbide-5-mononitrato stabilizzato e formulazioni cosi' ottenute
DE3540150A1 (de) 1985-11-13 1987-05-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
GB8531071D0 (en) 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
ES2031462T3 (es) 1986-03-24 1992-12-16 Nippon Kayaku Kabushiki Kaisha Procedimiento para producir 1-b-d-arabinofuranosilcitosina-5'-estearilfosfato monosodico y monohidrato de la misma, y compuesto farmaceutico que contiene esta ultima.
DE3623397A1 (de) 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3626058A1 (de) 1986-08-01 1988-02-11 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
EP0275821B1 (de) 1986-11-21 1992-02-26 Ciba-Geigy Ag Neue substituierte Alkandiphosphonsäuren
DE3700772A1 (de) 1987-01-13 1988-07-21 Inst Khim Kinetiki I Gorenija Verfahren zur herstellung von i-funktionellsubstituierten alkyliden-i,i-diphosphonsaeuren und deren gemischen
US5091525A (en) 1987-10-07 1992-02-25 Eli Lilly And Company Monohydrate and DMF solvates of a new carbacephem antibiotic
US5035898A (en) 1987-11-27 1991-07-30 Schering Corporation Potassium/magnesium supplement
US5110807A (en) 1988-12-01 1992-05-05 Ciba-Geigy Corporation Araliphatylaminoalkanediphosphonic acids
DE3822650A1 (de) 1988-07-05 1990-02-01 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3917153A1 (de) 1989-05-26 1990-11-29 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
MX21452A (es) 1989-07-07 1994-01-31 Ciba Geigy Ag Preparaciones farmaceuticas que se administran en forma topica.
MX21453A (es) 1989-07-07 1994-01-31 Ciba Geigy Ag Preparaciones farmaceuticas que se administran en forma topica.
TW208013B (tr) 1990-03-01 1993-06-21 Daiichi Co Ltd
JPH06500112A (ja) 1990-08-21 1994-01-06 ジ・アップジョン・カンパニー 抗関節炎剤としてのビスホスホン酸誘導体
US5039819A (en) 1990-09-18 1991-08-13 Merck & Co., Inc. Diphosphonate intermediate for preparing an antihypercalcemic agent
IT1246992B (it) 1991-01-08 1994-12-12 Gentili Ist Spa Procedimento per la preparazione di acidi difosfonici e loro sali
DK58291D0 (da) 1991-04-02 1991-04-02 Novo Nordisk As Krystalinsk stof og dets fremstilling
ES2149781T3 (es) * 1991-11-22 2000-11-16 Procter & Gamble Pharma Composiciones de risedronato de liberacion retardada.
SE501389C2 (sv) 1992-04-24 1995-01-30 Leiras Oy Farmaceutiskt preparat och förfarande för dess framställning
US5317015A (en) 1992-05-01 1994-05-31 Rhone-Poulenc Rorer Pharmaceuticals Inc. Azacyclic bisphosphonates as anticholesterolemic agents
WO1994000462A1 (en) 1992-06-23 1994-01-06 Yamanouchi Pharmaceutical Co., Ltd. Novel crystal of monohydrate of heterocyclic bis(phosphonic acid) derivative
FR2694558B1 (fr) 1992-08-05 1994-10-28 Sanofi Elf Monohydrate du sel disodique de l'acide 4-chlorophénylthiométhylène bisphosphonique, sa préparation, les compositions pharmaceutiques en contenant.
US5312925A (en) 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
BR9406332A (pt) 1993-04-28 1995-12-26 Pfizer Mono-hidrato cristalino de espirostanil-glicosidal
US5510517A (en) 1993-08-25 1996-04-23 Merck & Co., Inc. Process for producing N-amino-1-hydroxy-alkylidene-1,1-bisphosphonic acids
TW257765B (tr) * 1993-08-25 1995-09-21 Merck & Co Inc
US5580977A (en) 1995-03-01 1996-12-03 Eli Lilly And Company Process for preparing loracarbef monohydrate
TW393488B (en) 1995-04-20 2000-06-11 Merck & Co Inc Process for making 1-hydrox-ybisphosphonates
US5656288A (en) * 1995-06-08 1997-08-12 Sanofi Winthrop, Inc. Stable pharmaceutical compositions containing tiludronate hydrates and process for producing the pharmaceutical compositions
DE69722190T2 (de) 1996-02-14 2004-05-27 Itzhak Binderman Topische bisphosphonate zur verhinderung der knochenresorption
AU712710B2 (en) 1996-05-17 1999-11-11 Merck Sharp & Dohme Corp. Effervescent bisphosphonate formulation
US5730715A (en) 1996-06-14 1998-03-24 Becton Dickinson And Company Method for the iontophoretic administration of bisphosphonates
KR100192215B1 (ko) 1996-09-03 1999-06-15 강재헌 3-아미노-1-히드록시프로판-1,1-디포스폰산의 제조방법
TR200000111T2 (tr) * 1997-06-11 2000-05-22 The Procter & Gamble Company Gelişmiş üst gastrointestinal traktus güvenliği için film kaplı tablet.
ATE280173T1 (de) * 1997-07-15 2004-11-15 Gador Sa Kristalline form von n,n-dimethyl-3-amino-1- hydroxypropan-1,1-diphosphonsäure mononatriumsalz monohydrat und ein verfahren zu ihrer herstellung
US6432932B1 (en) * 1997-07-22 2002-08-13 Merck & Co., Inc. Method for inhibiting bone resorption
CA2335471A1 (en) * 1998-06-24 1999-12-29 Merck & Co., Inc. Compositions and methods for inhibiting bone resorption
AU2270101A (en) * 1999-12-20 2001-07-03 Merck & Co., Inc. Pharmaceutical kit
PE20011061A1 (es) * 2000-02-01 2001-11-20 Procter & Gamble Cristalizacion selectiva del acido 3-piridil-1-hidroxi-etiliden-1,1-bisfosfonico sodio como el hemipentahidrato o el monohidrato

Also Published As

Publication number Publication date
JP2016028083A (ja) 2016-02-25
HK1051046B (zh) 2005-04-29
DK1252170T4 (da) 2014-01-20
BR0107921A (pt) 2002-10-22
RU2236415C2 (ru) 2004-09-20
IL150511A (en) 2006-12-10
KR100549038B1 (ko) 2006-02-02
CO5271720A1 (es) 2003-04-30
EP1252170A2 (en) 2002-10-30
EP1252170B1 (en) 2004-08-18
WO2001056983A3 (en) 2002-03-07
JP2012255013A (ja) 2012-12-27
CN1183148C (zh) 2005-01-05
ES2225481T3 (es) 2005-03-16
HUP0204203A3 (en) 2005-02-28
JP5900553B2 (ja) 2016-04-06
BRPI0107921B8 (pt) 2021-05-25
ZA200205090B (en) 2003-04-30
JP2003521532A (ja) 2003-07-15
NO329923B1 (no) 2011-01-24
JP5859930B2 (ja) 2016-02-16
PL357097A1 (en) 2004-07-12
AU784307B2 (en) 2006-03-09
HK1051046A1 (en) 2003-07-18
KR20020071976A (ko) 2002-09-13
CN1396926A (zh) 2003-02-12
NZ519966A (en) 2004-03-26
AR030187A1 (es) 2003-08-13
CA2399976C (en) 2007-03-27
EP1252170B2 (en) 2013-11-06
NO20023645D0 (no) 2002-07-31
NO20023645L (no) 2002-10-01
HUP0204203A2 (en) 2003-05-28
BRPI0107921B1 (pt) 2020-11-10
CZ303400B6 (cs) 2012-08-29
WO2001056983A2 (en) 2001-08-09
TWI310769B (en) 2009-06-11
DE60104978T2 (de) 2005-08-18
MXPA02007417A (es) 2002-12-09
PT1252170E (pt) 2004-12-31
DE60104978D1 (de) 2004-09-23
ES2225481T5 (es) 2014-02-19
CA2399976A1 (en) 2001-08-09
JP2010159264A (ja) 2010-07-22
PL207589B1 (pl) 2011-01-31
DE60104978T3 (de) 2014-04-03
DK1252170T3 (da) 2004-12-13
PE20011061A1 (es) 2001-11-20
MA25654A1 (fr) 2002-12-31
AU3473601A (en) 2001-08-14
MY119968A (en) 2005-08-30
RU2002123369A (ru) 2004-01-10
JP5405343B2 (ja) 2014-02-05
US20020002282A1 (en) 2002-01-03
JP2014208716A (ja) 2014-11-06
IL150511A0 (en) 2003-02-12
SK11002002A3 (sk) 2003-02-04
US6410520B2 (en) 2002-06-25
SA01220066B1 (ar) 2006-11-25
ATE273984T1 (de) 2004-09-15
SK287884B6 (sk) 2012-02-03
HU230494B1 (hu) 2016-09-28

Similar Documents

Publication Publication Date Title
TR200402435T4 (tr) 3-piridil-1-hidroksietiliden-1,1-bisfosfonik asit sodyumun hemipentahidrat veya monohidrat olarak seçici şekilde kristalleştirilmesi.
MY119970A (en) Method of fertilizing an avian egg in the shell
EG24380A (en) Granule formulation
ZA200210092B (en) alpha crystalline form of perindopril tert-butylamine salt.
CR7333A (es) Forma poliforma de rimonabant, su procedimiento de preparacion y composiciones farmaceuticas que la contienen
NO20010957D0 (no) Nye hydratformer av alendronatnatrium, fremgangsmÕter for fremstilling av disse og farmasøytiske preparater derav
MY134123A (en) Citrate salt of 5,8,14-triazatetracyclo[10.3.1.0 2,11 .0 4,9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
HK1068866A1 (en) 3-phenyl-2-arylalkylthiopropionic acid derivatives as selective agonists of ppar-alpha
WO2002098850A3 (en) Chemical compounds and pharmaceutical compositions as cathepsin s inhibitors
WO2003087298A3 (en) Nucleosides preparation thereof and use as inhibitors of rna viral polymerases
WO2003051838A3 (en) Protein kinase inhibitors
AU2003258630A1 (en) Pyrimidine derivatives as selective cox-2 inhibitors
WO2002072581A3 (en) Pyrazolopyriadine derivatives
AU2002357740A1 (en) Pyrazolo-pyridine derivatives as antiherpes agents
ZA200101451B (en) Hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof.